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chronic renal failure (CRF) [1]. In reply to his queries
regarding questions 1 and 2, total ALP was significantly
increased; however, the majority of the patients had ac-
tivities within the reference interval for healthy adults.
We agree with the suggestion that the increase of BALP
isoform B2 in CRF patients may be clinically useful. Prediction of hypertension in
None of the patients in this study had any biochemical
or clinical evidence of hepatic disorder. To answer the hemodialysis patients
third question, we used the previously reported reference
intervals for all three BALP immunoassay kits (Alk-
To the Editor: I have read with much interest thephase-B, Tandem-R Ostase and Tandem-MP Ostase)
and refer him to Figure 2 [1]. To respond to his fourth paper by Agarwal and Lewis [1] on prediction of hyper-
tension in chronic hemodialysis patients. In the introduc-question, discordant findings between different studies
are not uncommon, which probably reflects the heteroge- tion, the authors focus on the fact that it is still uncertain
which blood pressure measurement the clinician has toneity of bone disorders in CRF patients. We did, how-
ever, find a significant correlation between the novel adopt to define hypertension in these patients. There
is no question that in the general population 24-hourBALP isoform B1x and PTH, which might contribute
to the positive correlations previously reported [2]. ambulatory monitoring is a better measure than the of-
fice measure. It is well-documented that the ambulatoryWe suggested that B1x should be further evaluated as
a marker of adynamic bone disease. This will indeed estimate is superior to the office estimate for predicting
incident cardiovascular complications, as well as left ven-require a classification of patients by bone histomorpho-
metry, which was not obtained in this study. Although trical hypertrophy (LVH) [2], which is a valid surrogate
end point. Whether or not 24-hour ambulatory monitor-adynamic bone disease is usually associated with rela-
tively low parathyroid hormone (PTH) levels, PTH may ing predicts survival and cardiovascular complications in
the dialysis population still remains to be proved. Thisfail to discriminate between adynamic and moderate
hyperparathyroid states and even high PTH levels may is important mostly because two surveys have shown
that routine pre-dialysis blood pressure and 24-hour am-occur [3]. Another important point, discussed in our pa-
per [1], is that PTH was analyzed using a commercial bulatory monitoring explain to a similar degree the vari-
ance in left ventricular mass. Both the paper by Conlonassay originally reported to detect only the intact (1-84
PTH) circulating molecule. However, it has recently et al [3] and our study based on multivariate modelling
[4] have clearly shown the strength of the associationbeen demonstrated that a fragment (most likely the 7-84
PTH) interferes with this assay [4]. Thus, the PTH values between 24-hour ambulatory monitoring and left ventri-
cal mass is not superior to that of pre-dialysis bloodreported in our study (and other studies) might well be
